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Abstract
MIRAGE (Minimum Information Required for A Glycomics Experiment) is an initiative that was
created by experts in the fields of glycobiology, glycoanalytics and glycoinformatics to produce
guidelines for reporting results from the diverse types of experiments and analyses used in struc-
tural and functional studies of glycans in the scientific literature. As a sequel to the guidelines for
sample preparation (Struwe et al. 2016, Glycobiology, 26:907–910) and mass spectrometry data
(Kolarich et al. 2013, Mol. Cell Proteomics, 12:991–995), here we present the first version of guide-
lines intended to improve the standards for reporting data from glycan microarray analyses. For
each of eight areas in the workflow of a glycan microarray experiment, we provide guidelines for
the minimal information that should be provided in reporting results. We hope that the MIRAGE
glycan microarray guidelines proposed here will gain broad acceptance by the community, and
will facilitate interpretation and reproducibility of the glycan microarray results with implications
in comparison of data from different laboratories and eventual deposition of glycan microarray
data in international databases.
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Introduction
MIRAGE (Minimum Information Required for A Glycomics
Experiment) is an initiative that was created by experts in the fields of
glycobiology, glycoanalytics and glycoinformatics to produce guide-
lines for reporting results and facilitating the interpretation, evaluation
and reproduction of data obtained from the diverse types of analyses
used in structural and functional studies of glycans (http://www.
beilstein-mirage.org). The history of this initiative and its three-
component organization: coordinating group, working group and
advisory board, have been reported previously (York et al. 2014).
Assignments of glycan structures as ligands or antigens increas-
ingly depend on glycan microarray-based binding analyses, and
accurate interpretation of results requires knowing the structures of
the arrayed glycans. The preparation and characterization of the gly-
cans depend on numerous techniques among them gel filtration,
liquid chromatography, capillary electrophoresis, nuclear magnetic
resonance and various types of mass spectrometry (MS). The infor-
mation derived from the techniques used needs to be reported to
enable a meaningful evaluation of the structure assignments. A
working group comprises investigators, who have participated in
the development and application of these methods, has been devel-
oping guidelines that are overseen by an advisory group and cri-
tiqued by the greater scientific community. These activities have
already resulted in MIRAGE guidelines intended to improve the
standards for reporting MS-based glycoanalytical data (Kolarich
et al. 2013) and glycan sample preparation (Struwe et al. 2016).
There are similarities among DNA, protein and glycan micro-
array technologies, although the methods of analysis, the informa-
tion sought and the conclusions from the different types of arrays
are very different. Microarrays, being comprised of libraries of
numerous elements (probes) that are simultaneously analyzed using
many samples (binders), create unique challenges in documentation
of data. Thus, early in the development of DNA arrays, Brazma and
coworkers saw the need for a public repository for the data (Brazma
et al. 2000). They realized that support of these databases would
require major efforts in bioinformatics to capture the essential infor-
mation, with definition of ontologies and formats to store the infor-
mation, and tools for searching the databases. These considerations
led to the development of “the Minimum Information for A
Microarray Experiment (MIAME) that described the minimum
information required to ensure that microarray data can be easily
interpreted and that results derived from its analysis can be inde-
pendently verified” (Brazma et al. 2001). This effort was successful
and is predictably being applied to other technologies. Today, most
data repositories for DNA expression based on arrays are compliant
with MIAME, and the MIAME guidelines are now required to be
followed for publishing in most scientific journals (Brazma 2009).
Investigations of protein–glycan interactions by studying glycan-
binding proteins (GBPs), such as lectins and antibodies, and their
binding to immobilized glycoconjugates or glycans have been con-
ducted for decades (Magnani et al. 1980, Tang et al. 1985); however,
the development of this approach as a high throughput method has
required expansion of the library of glycans used for printing arrays.
A pioneering effort in the area was the development of the procedure
to convert reducing glycans to neoglycolipids (Stoll et al. 1990) that
could be applied as 2mm bands or 300 µm spots on silica gel TLC
plates, nitrocellulose or PVDF membranes for monovalent immobil-
ization and subsequently probed with biologically relevant GBPs
(Fukui et al. 2002). A number of laboratories were active in develop-
ing the miniaturization of glycan arrays, which has also driven the
development of synthetic and chemo-enzymatic approaches to expand
libraries of glycans to populate large arrays (Magnani et al. 1980;
Tang et al. 1985; Drickamer and Taylor 2002; Love and Seeberger
2002; Feizi et al. 2003; Schwarz et al. 2003; Ratner et al. 2004).
However, it was the development of a microarray of 200 defined gly-
cans (Blixt et al. 2004) and its evolution to over 600 glycans by the
Consortium for Functional Glycomics (CFG) that generated much
interest in this approach, in part due to the free services of the
Protein–Glycan Interaction Service of the CFG that were made avail-
able to the scientific community through the NIGMS of the NIH
(http://www.functionalglycomics.org).
Data from microarrays of defined glycans are generally used to
determine the binding specificity of a given GBP by comparing the
structural details of bound and non-bound glycans in the array. Such
data have been extremely valuable in providing information on the
specificities of GBPs that mediate host–pathogen interactions, innate
and adaptive immunity and many other functions involving glycan
recognition. The websites of CFG (http://www.functionalglycomics.org)
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and of the Glycosciences Laboratory at Imperial College London
(https://www.imperial.ac.uk/glycosciences) contain information on the
glycans available on their microarray platforms and summaries of the
microarray binding data. Interpretation of the microarray data is
dependent on the composition of the library of glycans printed on the
array. Assignment of the ligand can best be made when the library
contains a series of closely related glycan structures that are bound or
not bound, but the conclusions are not necessarily unequivocal if the
array does not contain the relevant glycome.
Ideally, the biological relevance of an assignment made by glycan
array analysis should be evaluated by cellular or other in vivo analyses
using the glycans assigned as ligands. Ultimately, the full spectrum of
the biologically relevant determinants for a GBP can only be assessed
with a glycan microarray presenting all possible natural glycans in the
glycome in question. However, the largest glycan arrays of the CFG
and Glycosciences Laboratory at Imperial College London have only
600–800 glycans, whereas the human glycome has been estimated to
be comprising over 9000 glycan determinants (Cummings 2009).
Thus, there is ample opportunity to expand glycan microarrays to
more fully cover the diversity of structures in the human glycome.
Glycan arrays containing glycomes are only recently becoming avail-
able and they enable the “preferred” natural ligands residing therein
to be detected (Gao et al. 2014; Yu et al. 2014).
Apart from general screening analyses for defining the glycan
determinants recognized by GBPs, glycan arrays are used as collec-
tions of defined glycan substrates for experiments to determine spe-
cificities of glycosidases and glycosyltransferases (Blixt et al. 2008;
Chaubard et al. 2012); this involves the detection of specific altera-
tions of the substrates following incubation with the enzymes. The
use of glycan arrays for profiling anti-glycan antibody populations
in serum is also of interest, as this could potentially lead to discover-
ies of glycan antigen determinants that are relevant to vaccine
design, diagnostic assays and antibody-based therapies (Schneider
et al. 2015; Muthana and Gildersleeve 2016).
As glycans become more readily available, interest in developing
glycan microarrays has increased, and there have been several hun-
dred articles published on this topic. However, there is no common
experimental protocol, and many parameters involved in the design
and production of glycan microarrays are unfamiliar to reviewers
and editors of manuscripts reporting data using this technique.
There are numerous methods of creating glycan arrays using various
chemistries for attachment, different linkage structures (tags) and
even post-immobilization modifications.
Here, we report guidelines (Supplementary data) intended to
improve the standards for reporting data from experiments and ana-
lyses using glycan microarrays. These guidelines are intentionally min-
imal and apply only to information on generating glycan arrays and
producing interpretable data for follow-on experiments. The purpose
of these guidelines is not to cover every possible technique that can be
used to create glycan microarrays, but rather to identify and highlight
what parameters are important and should be reported in producing
and analyzing glycan microarrays so that published data can be reliably
interpreted by both the trained and untrained reader. We hope that the
MIRAGE guidelines proposed here will gain broad acceptance by the
community and thus will be as successful as the MIAME guidelines.
Eight parts of MIRAGE glycan microarray
guidelines
In developing MIRAGE guidelines for glycan microarrays, we
attempted to follow the basic principles used for MIAME (Brazma
et al. 2001), which required that the information about each experi-
ment be sufficient to reproduce it, to interpret and compare results
of similar experiments and be sufficiently structured so that data can
be usefully queried, analyzed and mined. We designate eight compo-
nents based on the workflow of a glycan microarray experiment
(Figure 1).
The guidelines are provided in the Supplementary data and also
on the website of the Beilstein-Institut (doi:10.3762/mirage.3). In
brief, Part 1 is about the glycan-binding sample. The term “Sample”
is used for the entities being analyzed for glycan recognition
throughout the guidelines. A wide variety of Samples can be applied
onto glycan microarrays. The minimum information required
includes description of Sample, modifications of Sample (if labeled
for example) and assay protocols. Part 2 is about the glycan library
from which the glycan array is generated. The arrays may comprise
glycans or glycoconjugates that are structurally defined; alternatively
they may be partially purified and their structures unknown as in
“shotgun” glycan arrays (Song et al. 2011; Yu et al. 2012, 2014;
Byrd-Leotis et al. 2014); or they may be glycans in fractions on their
way to being isolated from ligand positive macromolecules for char-
acterization as in “designer” arrays (Palma et al. 2006, 2015; Gao
et al. 2014). The guidelines under these parts include descriptions
for defined and undefined glycans that are being interrogated in the
arrays, as well as methods of modifications (functionalization or
derivatization) of glycans before arraying process.
The properties of the surface used to present the printed glycans
are covered in Part 3, and include types of surfaces, manufacturer
information and custom preparation of surface where applicable.
The method for immobilization (non-covalent or covalent) should
also be described here. Part 4 addresses the printing robot (arrayer
or printer) used to deliver the glycans onto the array surface.
Information should be provided on the instrument, dispensing mech-
anism, glycan deposition (volume and number of replicates of each
glycan) and printing conditions including post printing treatment.
Part 5 is about the layout of glycans in the array. The minimum
information required includes array geometry (e.g. single large
array, subarrays, microtiter plate), numbers of spots for each glycan
and in each array, identities of the printed glycans and methods for
validating the identities (e.g. binding data from the array using
Samples with known specificities). Part 6 speaks to the means of
detecting the binding and processing of the microarray data.
Fig. 1. The eight major parts of the MIRAGE Glycan Microarray Guidelines
(Supplementary data). Parts 1–6 mainly deal with generation of glycan
microarrays, microarray binding experiments, detection and data quantita-
tion, and Parts 7 and 8 focus on data presentation and interpretation in
publications.
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Fluorescence scanning is currently the most commonly used detec-
tion method. The present version of the guidelines includes descrip-
tions of scanning hardware, scanner settings (resolution, laser
channel, photomultiplier (PMT) gain and scan power) and image
analysis software used to quantify the output scanner image. The
method used for data processing to obtain data in a table of results
should also be described. Part 7 and Part 8 are about presentation
of glycan array data and a brief comment on interpretation of data,
respectively.
The majority of members of the MIRAGE Commission support
the view that images of microarray experiments are not essential as
minimal information at this time, but that the TIFF files, which
represent the raw data, and accompany “detailed glycan map” [e.g.
GenePix Array List (GAL) file, the text file with specific information
about the location, size and name of each glycan spot on the array
slide] and quantitation output files [e.g. proscan or GenePix Results
(GPR) files], should be saved for future use once glycan array data-
bases are available. The microarray images can be extremely inform-
ative with regard to assessing the background staining that can
sometimes obscure positive results or even generate false positive
results. Therefore, representative array images (reduced in size to
accommodate easy transfer of data) can certainly strengthen the
data in a manuscript or a database.
Discussion
The MIRAGE guidelines aim to establish uniformity in the description
of glycan microarrays and in the data collected without imposing rules
on how the experiments should be performed. Applying the guidelines
will not only facilitate interpretation and reproducibility of the results
but also facilitate comparison of results obtained by different labora-
tories and eventual deposition of these results in databases. These will
in turn enable development and use of data mining tools. Although
databases presenting glycan array data are currently available
online from the CFG (http://www.functionalglycomics.org) and the
Glycosciences Laboratory at Imperial College London (https://www.
imperial.ac.uk/glycosciences), they are not open to deposition of data
from other glycan microarrays, nor are they readily comparable.
These guidelines will stimulate the development of more universal
tools as seen with the MIAME guidelines for RNA/DNA microarrays.
For example, data submission tools will need to be developed enab-
ling users to enter MIRAGE information directly into a repository or
to export data in a standard format. A file format (digital standard
format) with well-defined terms (standard representations: ontologies
and dictionaries) for representing MIRAGE information in the com-
puter will also be developed and this is among the next steps of the
MIRAGE group. Efforts have been made to develop data mining soft-
ware to discover glycan-binding motifs based on currently available
glycan microarray data (Cholleti et al. 2012; Xuan et al. 2012; Aoki-
Kinoshita 2013, 2015; Kletter et al. 2013; Agravat et al. 2014;
Ichimiya et al. 2014).
This is the first version of the commentary on the MIRAGE
guidelines for a glycan array experiment. Hopefully, the reviewers
and editors of leading scientific journals will adopt the minimum
information suggested by MIRAGE so that MIRAGE-supportive
public repositories and databases can be established. Future versions
will conform to progress in the technologies and analyses as well as
wisdom from experience gained in the glycan microarray commu-
nity. By analogy with other large-scale experiments in life sciences,
data sharing and analysis tools will need to be developed and made
available to researchers for comparing data across different
laboratories. It is hoped that such an approach will become the
norm for glycan arrays so that data presentation and publication
standards are developed and lend themselves to annotation. We
shall look forward to having comments and suggestions from the
scientific research community, and will ensure that there will be
effective routes for transmitting these for our attention.
Availability
This manuscript describes the glycan microarray guidelines
(Version 1.0) as of June 2016. The current versions of all
MIRAGE guidelines and examples are available on the MIRAGE
project website (http://www.beilstein-institut.de/en/projects/
mirage/guidelines): sample preparations guidelines (doi:10.3762/
mirage.1), MS guidelines (doi:10.3762/mirage.2) and glycan
microarray guidelines (doi:10.3762/mirage.3).
Supplementary data
Supplementary data for this article is available online at http://glycob.
oxfordjournals.org/.
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